HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE AND BCNU WITH NON-CRYOPRESERVED AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS HODGKIN'S LYMPHOMA

被引：0
|
作者：
Brahimi, M. [1 ]
Yafour, N. [1 ]
Osmani, S. [1 ]
Attaf, F. [1 ]
Tadj, H. [1 ]
Arabi, A. [1 ]
Soltan, B. Enta [1 ]
Berredouane, H. [1 ]
Benzineb, B. [1 ]
Bey, M. [1 ]
Bahlat, N. [1 ]
Bekadja, M. A. [1 ]
机构：
[1] Univ Hosp Oran 1st November, Oran, Algeria
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1672
引用
收藏
页码：655 / 656
页数：2
相关论文
共 50 条
  • [31] Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin’s Lymphoma
    Li-na Han
    Jin Zhou
    Takayuki Hirose
    Yosuke Imai
    Takuro Ishiguro
    Takaaki Chou
    International Journal of Hematology, 2006, 84 : 174 - 181
  • [32] Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma
    Han, Li-na
    Zhou, Jin
    Hirose, Takayuki
    Imai, Yosuke
    Ishiguro, Takuro
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2006, 84 (02) : 174 - 181
  • [33] A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Nademanee, A
    Forman, S
    Molina, A
    Fung, H
    Smith, D
    Dagis, A
    Kwok, C
    Yamauchi, D
    Anderson, AL
    Falk, P
    Krishnan, A
    Kirschbaum, M
    Kogut, N
    Nakamura, R
    O'Donnell, M
    Parker, P
    Popplewell, L
    Pullarkat, V
    Rodriguez, R
    Sahebi, F
    Smith, E
    Snyder, D
    Stein, A
    Spielberger, R
    Zain, J
    White, C
    Raubitschek, A
    BLOOD, 2005, 106 (08) : 2896 - 2902
  • [34] High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma
    Falzetti, Franca
    Di Ianni, Mauro
    Ballanti, Stelvio
    Iodice, Giuseppe
    Reale, Antonia
    Minelli, Olivia
    Serio, Gabriella
    Martelli, Massimo F.
    Dammacco, Franco
    Vacca, Angelo
    Ria, Roberto
    CLINICAL AND EXPERIMENTAL MEDICINE, 2012, 12 (03) : 165 - 171
  • [35] Efficacy of high-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin's lymphoma.
    Metcalfe, TL
    Gooley, TA
    Press, OW
    Pagel, JM
    Petersdorf, SH
    Bensinger, W
    Holmberg, L
    Maloney, DG
    Gopal, AK
    BLOOD, 2005, 106 (11) : 589A - 589A
  • [36] High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma
    Franca Falzetti
    Mauro Di Ianni
    Stelvio Ballanti
    Giuseppe Iodice
    Antonia Reale
    Olivia Minelli
    Gabriella Serio
    Massimo F. Martelli
    Franco Dammacco
    Angelo Vacca
    Roberto Ria
    Clinical and Experimental Medicine, 2012, 12 : 165 - 171
  • [37] Autologous tandem transplantation with high-dose etoposide mobilised peripheral blood stem cells in patients with refractory Hodgkin's and aggressive non-Hodgkin lymphoma
    Sieniawski, M
    Glossmann, JP
    Staak, JO
    Nogova, L
    Kisro, J
    Rudolph, C
    Reiser, M
    Scheid, C
    Engert, A
    Diehl, V
    Josting, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S251 - S252
  • [38] Evaluation of busulfan, cyclophosphamide, and etoposide as a preparation regimen for autologous stem cell transplantation in Hodgkin's lymphoma patients
    Bicim, Soykan
    Erkurt, Mehmet Ali
    Kuku, Irfan
    Kaya, Emin
    Berber, Ilhami
    Kaya, Ahmet
    Hidayet, Emine
    Uysal, Ayse
    Sarici, Ahmet
    Ozen, Ilknur Nizam
    IRAQI JOURNAL OF HEMATOLOGY, 2024, 13 (01) : 1 - 6
  • [39] Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation
    Wadehra, Navin
    Farag, Sherif
    Bolwell, Brian
    Elder, Patrick
    Penza, Sam
    Matt, Kalaycio
    Avalos, Belinda
    Pohlman, Brad
    Marcucci, Guido
    Sobecks, Ronald
    Lin, Thomas
    Andresen, Steven
    Copelan, Edward
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (12) : 1343 - 1349
  • [40] A phase I and pharmacokinetic study of paclitaxel incorporated into the "augmented" high-dose cyclophosphamide, carmustine and etoposide (CBV) as conditioning chemotherapy for autologous stem cell transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Gokmen, E
    Callander, N
    Alexander, J
    Morris, A
    Tsai, TW
    Rosen, DM
    Anderson, J
    Alsina, M
    Craig, F
    Holle, L
    Cruz, J
    Baltathakis, I
    Hilsenbeck, S
    Valley, A
    West, L
    Egorin, MJ
    Freytes, CO
    BLOOD, 1999, 94 (10) : 320B - 320B
12345